The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat, M., VanRens, J.C., Laufersweiler, M.J., Brugel, T.A., Maier, J., Golebiowski, A., De, B., Easwaran, V., Hsieh, L.C., Walter, R.L., Mekel, M.J., Evdokimov, A., Janusz, M.J.(2006) Bioorg Med Chem Lett 16: 5973-5977
- PubMed: 16997556 
- DOI: https://doi.org/10.1016/j.bmcl.2006.08.132
- Primary Citation of Related Structures:  
2HK5 - PubMed Abstract: 
This communication details the synthesis, biological activity, and binding mode of a novel class of 2-benzimidazole substituted pyrimidines. The most potent analogs disclosed showed low nanomolar activity for the inhibition of Lck kinase and a representative analog was co-crystallized with Hck (a structurally related member of the Src family kinases).
Organizational Affiliation: 
Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Rd., Mason, OH 45040, USA. Mark.Sabat@Takedasd.com